TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while newer biologics (i.e., Takeda’s Entyvio, a CAM inhibitor, and Janssen’s Stelara, an IL-12/23 inhibitor) are mostly used as later-line therapies, following anti-TNF failure. These agents all have safety risks and efficacy limitations, and the launch of biosimilar alternatives has only increased the complexity of CD treatment. Furthermore, significant need remains, especially in the treatment of patients refractory to available therapies and patients with fistulizing disease.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 32 European gastroenterologists fielded in April 2021
Key companies: AbbVie, Janssen, Takeda, UCB, Celltrion Healthcare
Key drugs: Humira and infliximab biosimilar (IV), Remicade, Entyvio, Stelara, Cimzia, adalimumab biosimilar, Remsima SC